In our inaugural 2016 U.S. Transparency Report, we emphasized its commitment to clinical data transparency, responsible pricing, patient access and substantial investment in research and development (R&D). The report highlighted an average list price increase of 8.5%, an average net price increase of 3.5% after discounts and rebates, and a total of $11 billion provided in discounts and rebates. Additionally, we invested 55% more in R&D than in marketing and sales, underscoring its dedication to innovation.
Read the executive summary below, or view the full report here.
All figures according to Johnson & Johnson internal financial accounting. Figures have been rounded.